IEEE

An Efficient Approach for Two-Dimensional Parameter Estimation of a Single-Tone

Abstract: In this paper, parameter estimation of a two-dimensional (2-D) single damped real/complex tone in the presence of additive white Gaussian noise is addressed. By utilizing the rank-one ...
IEEE

Two-parameter robust repetitive control with application to a novel dual-stage actuator for noncircular Machining

Abstract: This work presents a robust repetitive controller design for a novel dual-stage actuator system. The dual-stage actuator, which consists of an electrohydraulic actuator for 25-mm-gross ...
Yahoo Finance

Recursion Pharmaceuticals: Q2 Earnings Snapshot

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Nasdaq

MIT and Recursion Unveil Boltz-2: A Revolutionary Open-Source Biomolecular Co-Folding Model with Advanced Structure and Binding Affinity Prediction

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...
Investing

Recursion strengthens board with two key appointments

SALT LAKE CITY – Recursion, a clinical-stage TechBio company listed on NASDAQ: RXRX, has announced the appointment of two new members to its Board of Directors. Namandjé Bumpus, Ph.D., and Elaine Sun ...
BioSpace

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse events In comparison to placebo, treatment with REC-994 400 mg showed ...
Investing

Recursion advances two cancer drug trials

SALT LAKE CITY - Recursion Pharmaceuticals (NASDAQ: RXRX), a clinical stage company specializing in drug discovery with a market capitalization of $2.28 billion, has received regulatory clearance to ...
Yahoo Finance

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors REC-4539, a ...
Mena FN

Recursion And Exscientia, Two Leaders In The AI Drug Discovery Space, Have Officially Combined To Advance The Industrialization Of Drug Discovery

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...
PharmiWeb

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides ...

SALT LAKE CITY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient ...